Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28931229 | 1.00 | L3MBTL1 (0.56) | L3MBTL1KMT2ACYP1A2CYP2C19LMNA | |
| SCHEMBL29819690 | 0.87 | KMT2A (0.61) | L3MBTL1KMT2ASMN1; SMN2CYP3A4MAPK14 | |
| SCHEMBL28931232 | 0.87 | KMT2A (0.47) | L3MBTL1KMT2ACYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL23521860 | 0.87 | KMT2A (0.61) | L3MBTL1KMT2ASMN1; SMN2CYP3A4MAPK14 | |
| SCHEMBL29808056 | 0.85 | CYP2C19 (0.58) | KMT2ACYP1A2CYP2C19LMNASMN1; SMN2 | |
| SCHEMBL23521747 | 0.85 | CYP2C19 (0.58) | KMT2ACYP1A2CYP2C19LMNASMN1; SMN2 | |
| SCHEMBL23521924 | 0.85 | KMT2A (0.55) | L3MBTL1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL29537243 | 0.85 | SMN1; SMN2 (0.57) | L3MBTL1LMNASMN1; SMN2CYP3A4MAPK14 | |
| SCHEMBL29808051 | 0.85 | KMT2A (0.55) | L3MBTL1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL28675585 | 0.85 | SMN1; SMN2 (0.57) | L3MBTL1LMNASMN1; SMN2CYP3A4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310955-B2 | Cyclic amide compounds for rabies treatment and method thereof | IRIMAJIRI THERAPEUTICS INC. (JP) | 2025-05-27 | — | — | US | disclosed |
| US-20220331300-A1 | CYCLIC AMIDE COMPOUNDS FOR RABIES TREATMENT AND METHOD THEREOF | IRIMAJIRI THERAPEUTICS INC. (JP) | 2022-10-20 | — | — | US | disclosed |
| EP-3978076-A1 | CYCLIC AMIDE COMPOUNDS FOR RABIES TREATMENT AND METHOD THEREOF | Oita University Institute of Advanced Medicine, Inc. (JP) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331300-A1 | CYCLIC AMIDE COMPOUNDS FOR RABIES TREATMENT AND METHOD THEREOF | F12, RXFP3, AVPR1B | L3MBTL1 406/4885KMT2A 1818/4885CYP1A2 2531/4885 |
| US-12310955-B2 | Cyclic amide compounds for rabies treatment and method thereof | F12, RXFP3, AVPR1B | L3MBTL1 406/4885KMT2A 1818/4885CYP1A2 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.